Dendritic cells in allogeneic hematopoietic stem cell transplantation

References

• Banchereau J, Steinman R M. Dendritic cells and the control of immunity. Nature 1998; 392: 245–255
   PubMed Web of Science ®Google Scholar
• Hart D NJ. Dendritic cells: unique leukocyte populations which control the primary immune response. Blood 1997; 90: 3245–3287
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C, Hieny S, Scharton-Kersten T, et al. In vivo microbial stimulation induces a rapid CD40L-independent production of IL-12 by dendritic cells and their re-distribution to T cell areas. Journal of Experimental Medicine 1997; 186: 1819–1829
   PubMed Web of Science ®Google Scholar
• Dalod M, Salazar-Mather T P, Malmgaard L, et al. Interferon alpha/beta and interleukin 12 responses to viral infections: pathways regulating dendritic cell cytokine expression in vivo. Journal of Experimental Medicine 2002; 195: 517–528
   PubMed Web of Science ®Google Scholar
• Ludewig B, Ehl S, Karrer U, Odermatt B, Hengartner H, Zinkernagel R M. Dendritic cells efficiently induce protective antiviral immunity. Journal of Virology 1998; 272: 3812–3818
   Google Scholar
• Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor. Journal of Experimental Medicine 1994; 179: 1109–1118
   PubMed Web of Science ®Google Scholar
• Romani N, Reider N, Heuer M, et al. Generation of mature dendritic cells from human blood: an improved method with special regard to clinical applicability. Journal of Immunology Methods 1996; 196: 137–151
   PubMed Web of Science ®Google Scholar
• Bender A, Sapp M, Schuler G, Steinmann R M, Bhardwaj N. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. Journal of Immunology Methods 1996; 196: 121–135
   PubMed Web of Science ®Google Scholar
• Cella M, Scheidegger D, Palmer-Lehmann K, Lane P, Lanzavecchia A, Alber G. Ligation of CD40 on dendritic cells triggers production of high-levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. Journal of Experimental Medicine 1996; 184: 747–752
   PubMed Web of Science ®Google Scholar
• Fernandez N C, Lozier A, Flament C, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Natural Medicine 1999; 5: 405–411
   PubMed Web of Science ®Google Scholar
• Fujii S, Shimizu K, Kronenberg M, Steinman R M. Prolonged interferon-gamma producing NKT response induced with α-galactosylceramide-loaded dendritic cells. Natural Immunology 2002; 3: 867–874
   PubMed Web of Science ®Google Scholar
• De Jong E C, Smits H H, Kapsenberg M L. Dendritic cell-mediated T cell polarization. Springer Seminars in Immunology 2005; 26: 289–307
   PubMed Web of Science ®Google Scholar
• Steinman R M, Hawiger D, Nussenzweig M C. Tolerogenic dendritic cells. Annual Reviews in Immunology 2003; 21: 685–711
   PubMed Web of Science ®Google Scholar
• Baron F, Storb R, Little M T. Hematopoietic cell transplantation. Archives of Medical Research 2003; 34: 528–544
   PubMed Web of Science ®Google Scholar
• Storb R, Yu C, Wagner J L, et al. Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total antibody irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997; 89: 3048–3054
   PubMed Web of Science ®Google Scholar
• Kolb H J, Schattenberg A, Goldman J M, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European group for blood and marrow transplantation working party chronic leukemia. Blood 1995; 86: 2041–2050
   PubMed Web of Science ®Google Scholar
• Goulmy E. Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy. Immunology Review 1997; 157: 125–140
   PubMed Web of Science ®Google Scholar
• Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763
   PubMed Web of Science ®Google Scholar
• Giralt S, Estey E, Albitar M, et al. Engraftment of hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536
   PubMed Web of Science ®Google Scholar
• McSweeney P A, Niederwieser D, Shizuru J A, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400
   PubMed Web of Science ®Google Scholar
• Childs R, Chernoff A, Contentin N, et al. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem cell transplantation. New England Journal of Medicine 2000; 343: 750–758
   PubMed Web of Science ®Google Scholar
• Hentschke P, Barkholt L, Uzunel M, et al. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma. Bone Marrow Transplant 2003; 31: 253–261
   PubMed Web of Science ®Google Scholar
• MacDonald K PA, Munster D J, Clark G J, Dzionek A, Schmitz J, Hart D NJ. Characterization of human blood dendritic cell subsets. Blood 2002; 100: 4512–4520
   PubMed Web of Science ®Google Scholar
• Dzionek A, Fuchs A, Schmidt P, et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. Journal of Immunology 2000; 165: 6037–6046
   PubMed Web of Science ®Google Scholar
• Borras F, Matthews N, Lowdell M, Navarrete C. Identification of both myeloid CD11c + and lymphoid CD11c − dendritic cell subsets in cord blood. British Journal of Haematology 2001; 113: 925–931
   PubMed Web of Science ®Google Scholar
• Bender J G, Unverzagt K L, Walker D, et al. Identification and comparison of CD34-positive cells and their subpopulations from normal peripheral blood and bone marrow using multicolor flow cytometry. Blood 1991; 77: 2591–2596
   PubMed Web of Science ®Google Scholar
• Santiago-Schwarz F, Belilos E, Diamond B, Carson S E. TNF-α in combination with GM-CSF enhances the differentiation of neonatal cord blood stem cells into dendritic cells and macrophages. Journal of Leukocyte Biology 1992; 52: 274–281
   PubMed Web of Science ®Google Scholar
• Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995; 3: 459–473
   PubMed Web of Science ®Google Scholar
• Van Voorhis W C, Hair L S, Steinman R M, Kaplan G. Human dendritic cells. Enrichment and characterisation from peripheral blood. Journal of Experimental Medicine 1982; 155: 1172–1187
   PubMed Web of Science ®Google Scholar
• Young J W, Steinman R M. Accessory cell requirements for the MLR and polyclonal mitogens, as studied with a new technique for enriching blood dendritic cells. Cell Immunology 1988; 111: 167–182
   PubMed Web of Science ®Google Scholar
• Fearnly D B, Whyte L F, Carnoutsos S A, Cook A H, Hart D NJ. Monitoring human blood dendritic cell numbers in normal individuals and in stem cell transplantation. Blood 1999; 93: 728–736
   PubMed Web of Science ®Google Scholar
• Macatonia S E, Lau R, Patterson S, Pinching A J, Knight S C. Dendritic cell infection, depletion and dysfunction in HIV-infected individuals. Immunology 1990; 71: 38–45
   Web of Science ®Google Scholar
• Hunt D WC, Huppertz H -I, Jiang H -J, Petty R E. Studies of human cord blood dendritic cells: evidence for functional immaturity. Blood 1994; 84: 4333–4343
   PubMed Web of Science ®Google Scholar
• Liu E, Tu W, Law H KW, Lau Y L. Decreased yield, phenotypic expression and function of immature monocyte-derived dendritic cells in cord blood. British Journal of Haematology 2001; 113: 240–246
   PubMed Web of Science ®Google Scholar
• Sorg R V, Kögler G, Wernet P. Identification of cord blood dendritic cells a an immature CD11c- population. Blood 1999; 93: 2302–2307
   PubMed Web of Science ®Google Scholar
• Crespo I, Pavia A, Couceiro A, Pimentel P, Orfao A, Regateiro F. Immunophenotypic and functional characterization of cord blood dendritic cells. Stem Cells Development 2004; 13: 63–70
   PubMed Web of Science ®Google Scholar
• Gratwohl A. EBMT JACIE Accreditation office. Overview of transplant activity in Europe. Hemtology Journal 2004; 5(Suppl 3)29–33
   Google Scholar
• Cutler C, Giri S, Jeyapalan S, Paniagua D, Viswanathan A, Antin J H. Acute and chronic graft-versus-host disease after allogeneic peripheral-blood stem-cell and bone marrow transplantation. Journal of Clinical Oncology 2001; 19: 3685–3691
   PubMed Web of Science ®Google Scholar
• Horan J T, Liesveld J L, Fernandez I D, et al. Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials. Bone Marrow Transplant 2003; 32: 293–298
   PubMed Web of Science ®Google Scholar
• Körbling M, Anderlini P. Peripheral blood stem cell versus bone marrow allotransplantation: does the source of hematopoietic stem cell matter?. Blood 2001; 98: 2900–2908
   PubMed Web of Science ®Google Scholar
• Arpinati M, Green C L, Heimfeld S, Heuser J E, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 2000; 95: 2484–2490
   PubMed Web of Science ®Google Scholar
• Sloand E, Kim S, Maciejewski J, et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood 2000; 95: 2269–2274
   PubMed Web of Science ®Google Scholar
• Klangsinsirikul P, Russell N. Peripheral blood stem cell harvests from G-CSF-stimulated donors contain a skewed TH2 CD4 phenotype and a predominance of type 2 dendritic cells. Experimental Hematology 2002; 30: 495–501
   PubMed Web of Science ®Google Scholar
• Pan L, Delmonte J, Jalonen C, Ferrara J. Pretreatment of donor mice with granulocyte colony-stimulating factor polarizes T-lymphocytes towards type-2 cytokine production and reduced severity of experimental graft-versus-host disease. Blood 1995; 86: 4422–4429
   PubMed Web of Science ®Google Scholar
• Zeng D, Dejbakhsh-Jones S, Strober S. Granulocyte colony-stimulating factor reduces the capacity of blood mononuclear cells to induce graft-versus-host disease: impact on blood progenitor cell transplantation. Blood 1997; 90: 453–463
   PubMed Web of Science ®Google Scholar
• Krenger W, Snyder K M, Byon J C, Falzarano G, Ferrara J L. Polarized type 2 alloreactive CD4 + and CD8 + donor T cells fail to induce experimental acute graft-versus-host disease. Journal of Immunology 1995; 155: 585–593
   PubMed Web of Science ®Google Scholar
• Fowler D H, Kurasawa K, Smith R, Eckhaus M A, Gress R E. Donor CD4-enriched cells of TH2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994; 84: 3540–3549
   PubMed Web of Science ®Google Scholar
• Waller E K, Rosenthal H, Jones T W, et al. Larger numbers of CD4bright dendritic cells in donor bone marrow are associated with increased relapse after allogeneic bone marrow transplantation. Blood 2001; 97: 2948–2956
   PubMed Web of Science ®Google Scholar
• Kitabayashi A, Hirokawa M, Hatano Y, et al. Granulocyte colony-stimulating factor down-regulates allogeneic immune responses by posttranscriptional inhibition of tumor necrosis factor-α production. Blood 1995; 86: 2220–2227
   PubMed Web of Science ®Google Scholar
• Volpi I, Perruccio K, Tosti A, et al. Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood 2001; 97: 2514–2521
   PubMed Web of Science ®Google Scholar
• Krenger W, Hill G R, Ferrara J L. Cytokine cascades in acute graft-versus-host disease. Transplantation 1997; 64: 553–558
   PubMed Web of Science ®Google Scholar
• Parkman R, Weinberg K I. Immune reconstitution following hematopoietic cell transplantation. Thomas' hematopoietic cell transplantation, K G Blume, S J Forman, F R Appelbaum. Blackwell Publishing, OxfordUK 2004; 853–861, 3rd
   Google Scholar
• Chklovskaia E, Nowbakht P, Nissen C, Gratwohl A, Bargetzi M, Wodnar-Filipowicz A. Reconstitution of dendritic and natural killer-cell subsets after allogeneic stem cell transplantation: effects of endogenous flt ligand. Blood 2004; 103: 3860–3868
   PubMed Web of Science ®Google Scholar
• Auffermann-Gretzinger S, Lossos I S, Vayntrub T A, et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood 2002; 99: 1442–1448
   PubMed Web of Science ®Google Scholar
• Morse M A, Rizzieri D, Stenzel T T, et al. Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. Journal of Hematotherapy Stem Cell Research 2002; 11: 659–668
   PubMedGoogle Scholar
• Mohty M, Gaugler B, Faucher C, et al. Recovery of lymphocyte and dendritic cell subsets following reduced intensity allogeneic bone marrow transplantation. Hematology 2002; 7: 157–164
   PubMedGoogle Scholar
• Fagnoni F F, Oliviero B, Giorgiani G, et al. Reconstitution dynamics of plasmacytoid and myeloid dendritic cell precursors after allogeneic myeloablative hematopoietic stem cell transplantation. Blood 2004; 104: 281–289
   PubMed Web of Science ®Google Scholar
• Reddy V, Iturraspe J A, Tzolas A C, Meier-Kriesche H U, Schold J, Wingard J R. Low dendritic cell count after allogeneic hematopoietic stem cell transplantation predicts relapse, death, and acute graft-versus-host disease. Blood 2004; 103: 4330–4335
   PubMed Web of Science ®Google Scholar
• Mohty M, Blaise D, Faucher C, et al. Impact of plasmacytoid dendritic cells on outcome after reduced-intensity conditioning allogeneic stem cell transplantation. Leukemia 2005; 19: 1–6
   PubMed Web of Science ®Google Scholar
• Urbini B, Arpinati M, Bonifazi F, et al. Allogeneic graft CD34 + cell dose correlates with dendritic cell dose and clinical outcome, but not with dendritic cell reconstitution after transplant. Experimental Hematology 2003; 31: 953–958
   PubMed Web of Science ®Google Scholar
• Nachbaur D, Kircher B, Eisendle K, Lätzer K, Haun M, Gastl G. Phenotype, function and chimaerism of monocyte-derived blood dendritic cells after allogeneic haematopoietic stem cell transplantation. British Journal of Haematology 2003; 123: 119–126
   PubMed Web of Science ®Google Scholar
• Childs R, Clave E, Contentin N, et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999; 94: 3234–3241
   PubMed Web of Science ®Google Scholar
• Sullivan K M. Graft-vs.-Host Disease. Thomas' hematopoietic cell transplantation, K G Blume, S J Forman, F R Appelbaum. Blackwell Publishing, OxfordUK 2004; 635–664, 3rd ed
   Google Scholar
• Shlomchik W D, Couzens M S, Tang C B, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 1999; 285: 412–415
   PubMed Web of Science ®Google Scholar
• Chan G W, Gorgun G, Miller K B, Foss F M. Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease. Biology of Blood Marrow Transplant 2003; 9: 170–176
   PubMed Web of Science ®Google Scholar
• Duffner U A, Maeda Y, Cooke K R, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. Journal of Immunology 2004; 172: 7393–7398
   PubMed Web of Science ®Google Scholar
• Anderson B E, McNiff J M, Jain D, Blazar B R, Shlomchik W D, Shlomshik M J. Distinct roles for donor- and host-derived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: requirements depend on target organ. Blood 2005; 105: 2227–2234
   PubMed Web of Science ®Google Scholar
• Zhang Y, Louboutin J P, Zhu J, et al. Preterminal host dendritic cells in irradiated mice prime CD8 + T cell-mediated acute graft-versus-host disease. Journal of Clinical Investigations 2002; 109: 1335–1344
   PubMed Web of Science ®Google Scholar
• Ruggieri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097–2100
   PubMed Web of Science ®Google Scholar
• Zhang Y, Shlomchik D, Joe G, et al. APCs in the liver and spleen recruit activated allogeneic CD8 + T cells to elicit hepatic graft-versus-host disease. Journal of Immunology 2002; 169: 7111–7118
   PubMed Web of Science ®Google Scholar
• Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Natural Medicine 2004; 10: 510–517
   PubMed Web of Science ®Google Scholar
• Merad M, Manz M G, Karsunky H, et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Natural Immunology 2002; 3: 1135–1141
   PubMed Web of Science ®Google Scholar
• Emile J F, Haddad E, Fraitag S, Canioni D, Fischer A, Brousse N. Detection of donor-derived Langerhans cells in MHC class I immunodeficient patients after allogeneic bone marrow transplantation. British Journal of Haematology 1997; 98: 480–484
   PubMed Web of Science ®Google Scholar
• Matte C C, Liu J, Cormier J, et al. Donor APCs are required for maximal GVHD but not for GVL. Natural Medicine 2004; 10: 987–992
   PubMed Web of Science ®Google Scholar
• Takebayashi M, Amakawa R, Tajima K, et al. Blood dendritic cells are decreased in acute graft-versus-host disease. Bone Marrow Transplant 2004; 33: 989–996
   PubMed Web of Science ®Google Scholar
• Asagoe K, Takahashi K, Yoshino T, et al. Numerical, morphological and phenotypic changes in Langerhans cells in the course of murine graft-versus-host disease. British Journal of Dermatology 2001; 145: 918–927
   PubMed Web of Science ®Google Scholar
• Della Porta M, Rigolin G M, Alessandrino E P, et al. Dendritic cell recovery after allogeneic stem cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. European Journal of Haematology 2004; 72: 18–25
   PubMed Web of Science ®Google Scholar
• Arpinati M, Chirumbulo G, Bandini G, et al. Graft versus host disease affects DC2-recovery after allogeneic PBSC transplantation. Bone Marrow Transplant 2002; 29(Suppl. 2)175(Abstr. 661
   Google Scholar
• Clark F J, Freeman L, Dzionek A, et al. Origin and subset distribution of peripheral blood dendritic cells in patients with chronic graft-versus-host disease. Transplantation 2003; 75: 221–225
   PubMed Web of Science ®Google Scholar
• Sato K, Yamashita N, Baba M, Matsuyama T. Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 2003; 101: 3581–3589
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Schmitt E, Steinbrink K, Enk A H. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends in Immunology 2001; 22: 394–400
   PubMed Web of Science ®Google Scholar
• Cobbold S P, Nolan K F, Graca L, et al. Regulatory T cells and dendritic cells in transplantation tolerance: molecular markers and mechanisms. Immunology Reviews 2003; 196: 109–124
   PubMed Web of Science ®Google Scholar
• Hackstein H, Thomson A W. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nature Immunology 2004; 4: 24–34
   Web of Science ®Google Scholar
• Lagaraine C, Lebranchu Y. Effects of immunosuppressive drugs on dendritic cells and tolerance induction. Transplantation 2003; 75(Suppl)37–42
   PubMed Web of Science ®Google Scholar
• Moser M, De Smedt T, Sornasse T, et al. Glucocorticoids down-regulate dendritic cell function in vitro and in vivo. European Journal of Immunology 1995; 25: 2818–2824
   PubMed Web of Science ®Google Scholar
• Vanderheyde N, Verhasselt V, Goldman M, Willems F. Inhibition of human dendritic cell functions by methylprednisolone. Transplantation 1999; 67: 1342–1347
   PubMed Web of Science ®Google Scholar
• Woltman A M, de Fijter J W, Kamerling S WA, Paul L C, Daha M R, van Kooten C. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. European Journal of Immunology 2000; 30: 1807–1812
   PubMed Web of Science ®Google Scholar
• Auphan N, DiDonato J A, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270: 232–233
   PubMed Web of Science ®Google Scholar
• Shimizu K, Fujii S, Fujimoto K, et al. Tacrolimus (FK506) treatment of CD34 + hematopoietic progenitor cells promote the development of dendritic cells that drive CD4 + T cells towards Th2 responses. Journal of Leukocyte Biology 2000; 68: 633–640
   PubMed Web of Science ®Google Scholar
• Szabo G, Gavala C, Mandrekar P. Tacrolimus and cyclosporine A inhibit allostimulaory capacity and cytokine production of human myeloid dendritic cells. Journal of Investigative Medicine 2001; 49: 442–449
   PubMed Web of Science ®Google Scholar
• Salgado C G, Nakamura K, Sugaya M, et al. Differential effects of cytokines and immunosuppressive drugs on CD40, B7-1, and B7-2 expression on purified epidermal Langerhans cells. Journal of Investigative Dermatology 1999; 113: 1021–1027
   PubMed Web of Science ®Google Scholar
• Schuller E, Oppel T, Bornhovd E, Wetzel S, Wollenberg A. Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis. Allergy Clinics on Immunology 2004; 114: 137–143
   PubMed Web of Science ®Google Scholar
• Borghi-Cirri M B, Riccardi-Arbi R, Bacci S, et al. Inhibited differentiation of Langerhans cells in the rat epidermis upon systemic treatment with cyclosporin A. Histology & Histopathology 2001; 16: 107–112
   PubMed Web of Science ®Google Scholar
• Knight S C, Roberts M, Macatonia S E, Edwards A J. Blocking of acquisition and presentation of antigen by dendritic cells with cyclosporine. Studies with fluorescin isothiocyanate. Transplantation 1988; 46: 48–53
   Web of Science ®Google Scholar
• Robert M S, Knight S C. Low-dose immunosuppression by cyclosporine operating via antigen-presenting dendritic cells. Transplantation 1990; 50: 91–95
   PubMed Web of Science ®Google Scholar
• Dupuy P, Bagot M, Michel L, Descourt B, Dubertret L. Cyclosporin A inhibits antigen-presenting functions of freshly isolated Langerhans cells in vitro. Journal of Investigative Dermatology 1991; 96: 408–413
   PubMed Web of Science ®Google Scholar
• Demidem A, Taylor J R, Grammer S F, Streilein J W. Comparison of effects of transforming growth factor-beta and cyclosporin A on antigen-presenting cells of blood and epidermis. Journal of Investigations 1991; 96: 401–407
   Google Scholar
• Varey A M, Champion B R, Cooke A. Cyclosporine affects the function of antigen-presenting cells. Immunology 1986; 57: 111–114
   PubMed Web of Science ®Google Scholar
• Sauma D, Fierro A, Mora J R, et al. Cyclosporine preconditions dendritic cells during differentiation and reduces IL-2 and IL-12 production following activation: a potential tolerogenic effect. Transplantation Proceedings 2003; 35: 2515–2517
   PubMed Web of Science ®Google Scholar
• Hackstein H, Taner T, Zahorchak A F, Morelli A E, Logar A J, Gessner A, Thomson A W. Rapamycin inhibits IL-4-induced dendritic cell maturation in vitro and dendritic cell mobilization and function in vivo. Blood 2003; 101: 4457–4463
   PubMed Web of Science ®Google Scholar
• Hackstein H, Taner T, Logar A J, Thomson A W. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100: 1084–1087
   PubMed Web of Science ®Google Scholar
• Taner T, Hackstein H, Wang Z, Morelli A E, Thomson A W. Rapamycin-treated, alloantigen-pulsed host dendritic cells induce AG-specific T cell regulation and prolong graft survival. American Journal of Transplantation 2005; 5: 228–236
   PubMed Web of Science ®Google Scholar
• Monti P, Allavena P, Di Carlo V, Piemonti L. Effects of anti-lymphocytes and anti-thymocytes globulin on human dendritic cells. International Immunopharmacology 2003; 3: 189–196
   PubMed Web of Science ®Google Scholar
• Fang L, Fehse B, Engel M, Zander A, Kröger N. Antithymocyte globulin induces ex vivo and in vivo depletion of myeloid and plasmacytoid dendritic cells. Transplantation 2005; 79: 369–371
   PubMed Web of Science ®Google Scholar
• Ratzinger G, Reagan J L, Heller G, Busam K J, Young J W. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-versus-host interactions in transplantation. Blood 2003; 101: 1422–1429
   PubMed Web of Science ®Google Scholar
• Collin M P, Munster D, Clark G, Wang X N, Dickinson A M, Hart D N. In vitro depletion of tissue-derived dendritic cells by CMRF-44 antibody and alemtuzumab: implications for the control of graft-versus-host disease. Transplantation 2005; 27: 722–725
   Web of Science ®Google Scholar
• Klangsirikul P, Carter I G, Byrne J L, Hale G, Russell N H. Campath-1G causes rapid depletion of circulating host dendritic cells (DCs) before allogeneic transplantation but does not delay DC reconstitution. Blood 2002; 99: 2586–2591
   PubMed Web of Science ®Google Scholar
• Liu H N, Wong C K. In vitro immunosuppressive effects of methotrexate and azathioprine on Langerhans cells. Archives of Dermatology Research 1997; 289: 94–97
   PubMed Web of Science ®Google Scholar
• Mehling A, Grabbe S, Voskort M, et al. Mycophenolate mofetil impairs the maturation and function of murine dendritic cells. Journal of Immunology 2000; 165: 2374–2381
   PubMed Web of Science ®Google Scholar
• Colic M, Stojic-Vukanic Z, Pavlovic B, Jandric D, Stefanoska I. Mycophenolate mofetil inhibits differentiation, maturation and allostimulatory function of human monocyte-derived dendritic cells. Clinical & Experimental Immunology 2003; 134: 63–69
   PubMed Web of Science ®Google Scholar
• Greinix H T, Volc-Platzer B, Rabitsch W, et al. Successful use of extracorporeal photochemotherapy in the treatment of severe acute and chronic graft-versus-host disease. Blood 1998; 92: 3098–3104
   PubMed Web of Science ®Google Scholar
• Gorgun G, Miller K B, Foss F M. Immunologic mechanisms of extracorporeal photochemotherapy in chronic graft-versus-host diesease. Blood 2002; 100: 941–947
   PubMed Web of Science ®Google Scholar
• Riddell S R, Watanabe K S, Goodrich J M, Li C R, Agha M E, Greenberg P D. Restoration of viral immunity in immunodeficient humans by adoptive transfer of T cell clones. Science 1992; 257: 238–241
   PubMed Web of Science ®Google Scholar
• Walter E A, Greenberg P D, Gilbert M J, Finch R J, Watanabe K S, Thomas E D, Riddell S R. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. New England Journal of Medicine 1995; 333: 1038–1044
   PubMed Web of Science ®Google Scholar
• Einsele H, Roosnek E, Rufer N, et al. Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 2002; 99: 3916–3922
   PubMed Web of Science ®Google Scholar
• Hebart H, Brugger W, Grigoleit U, et al. Risk for cytomegalovirus disease in patients receiving polymerase chain reaction-based preemptive antiviral therapy after allogeneic stem cell transplantation depends on transplantation modality. Blood 2001; 97: 2183–2185
   PubMed Web of Science ®Google Scholar
• Singhal S, Shaw J C, Ainsworth J, et al. Direct visualization and quantitation of cytomegalovirus-specific CD8 + cytotoxic T-lymphocytes in liver transplant patients. Transplantation 2000; 69: 2251–2259
   PubMed Web of Science ®Google Scholar
• Engstrand M, Tournay C, Peyrat M A, et al. Characterization of CMVpp65-specific CD8 + T lymphocytes using MHC tetramers in kidney transplant patients and healthy participants. Transplantation 2000; 69: 2243–2250
   PubMed Web of Science ®Google Scholar
• Rauser G, Einsele H, Sinzger C, et al. Rapid generation of combined CMV-specific CD4 + and CD8 + T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 2004; 103: 3565–3372
   PubMed Web of Science ®Google Scholar
• Einsele H, Hebart H. CMV-Specific immunotherapy. Human Immunology 2004; 65: 558–564
   PubMed Web of Science ®Google Scholar
• Einsele H, Hebart H. Cellular immunity to viral and fungal antigens. Current Opinions in Hematology 2002; 9: 485–489
   PubMed Web of Science ®Google Scholar
• Romani L, Kaufmann S HE. Immunity to fungi. Research in Immunology 1998; 149: 277–281
   PubMedGoogle Scholar
• Buentke E, Scheynius A. Dendritic cells and fungi. APMIS 2003; 111: 789–796
   Web of Science ®Google Scholar
• Claudia M, Bacci A, Silvia B, Gaziano R, Spreca A, Romani L. The interaction of fungi with dendritic cells: implications for Th immunity and vaccination. Current Molecular Medicine 2002; 2: 507–524
   PubMedGoogle Scholar
• Braedel S, Radsak M, Einsele H, et al. Aspergillus fumigatus antigens activate innate immune cells via toll-like receptors 2 and 4. British Journal of Haematology 2004; 125: 392–399
   PubMed Web of Science ®Google Scholar
• Bozza S, Gaziano R, Spreca A, et al. Dendritic cells transport conidia and hyphae of aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th responses to the fungus. Journal of Immunology 2002; 168: 1362–1371
   PubMed Web of Science ®Google Scholar
• Bozza S, Montagnoli C, Gaziano R, et al. Dendritic cell-based vaccination against opportunistic fungi. Vaccine 2004; 22: 857–864
   PubMed Web of Science ®Google Scholar
• Bacci A, Montagnoli C, Perruccio K, et al. Dendritic cells pulsed with fungal RNA induce protective immunity to candida albicans in hematopoietic transplantation. Journal of Immunology 2002; 168: 2904–2913
   PubMed Web of Science ®Google Scholar
• Grazziutti M, Przepiorka D, Rex J H, Braunschweig I, Vadhan-Raj S, Savary C A. Dendritic cell-mediated stimulation of the in vitro lymphocyte response to Aspergillus. Bone Marrow Transplantation 2001; 27: 647–652
   PubMed Web of Science ®Google Scholar
• Ramadan G, Davies B, Kurup V P, Keever-Taylor C A. Generation of Th1 T cell responses directed to a HLA Class II restricted epitope from the Aspergillus f16 allergen. Clinical & Experimental Immunology 2005; 139: 257–267
   PubMed Web of Science ®Google Scholar
• Shao C, Qu J, He L, et al. Dendritic cells transduced with an adenovirus vector encoding interleukin-12 are a potent vaccine for invasive pulmonary aspergillosis. Genes in Immunology 2005; 6: 103–114
   PubMed Web of Science ®Google Scholar
• Bozza S, Perruccio K, Montagnoli C, et al. A dendritic cell vaccine against invasive aspergillosis in allogeneic hematopoietic transplantation. Blood 2003; 102: 3807–3814
   PubMed Web of Science ®Google Scholar
• Kolb H J, Schmid C, Barrett A J, Schendel D J. Graft-versus-leukemia reactions in allogeneic chimeras. Blood 2004; 103: 767–776
   PubMed Web of Science ®Google Scholar
• Mackinnon S, Papadopoulos E B, Carabasi M H, et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease. Blood 1995; 86: 1261–1268
   PubMed Web of Science ®Google Scholar
• Marks D I, Lush R, Cavenagh J, et al. The toxicity and efficacy of donor lymphocyte infusions given after reduced-intensity conditioning allogeneic stem cell transplantation. Blood 2002; 100: 3108–3114
   PubMed Web of Science ®Google Scholar
• Bleakley M, Riddell S R. Molecules and mechanisms of the graft-versus-leukaemia effect. Nature Reviews 2004; 4: 371–380
   Web of Science ®Google Scholar
• Spierings E, Wieles B, Goulmy E. Minor histocompatibility antigens—big in tumour therapy. Trends in Immunology 2004; 25: 56–60
   PubMed Web of Science ®Google Scholar
• Dallal R M, Lotze M T. The dendritic cell and human cancer vaccines. Current Opinions in Immunology 2000; 12: 583–588
   PubMed Web of Science ®Google Scholar
• Banchereau J, Schuler-Thurner B, Palucka A K, Schuler G. Dendritic cells as vectors for therapy. Cell 2001; 106: 271–274
   PubMed Web of Science ®Google Scholar
• Steinman R M, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. International Journal of Cancer 2001; 94: 459–473
   PubMed Web of Science ®Google Scholar
• Schuler G, Schuler-Thurner B, Steinman R M. The use of dendritic cells in cancer immunotherapy. Current Opinions in Immunology 2003; 15: 138–147
   PubMed Web of Science ®Google Scholar
• Reichardt V L, Brossart P. Current status of vaccination therapy for leukemias. Current Hematology Reports 2005; 4: 73–76
   PubMedGoogle Scholar
• Cathart K, Pinilla-Ibarz J, Korontsvit T, et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037–1042
   PubMed Web of Science ®Google Scholar
• Ossenkoppele G J, Stam A G, Westers T M, et al. Vaccination of chronic myeloid leukemia patients with autologous in vitro cultured dendritic cells. Leukemia 2003; 17: 1424–1426
   PubMed Web of Science ®Google Scholar
• Pinilla-Ibarz J, Cathcart K, Korontsvit T, et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000; 95: 1781–1787
   PubMed Web of Science ®Google Scholar
• Motta M R, Castellani S, Rizzi S, et al. Generation of dendritic cells from CD14 + monocytes positively selected by immunomagnetic adsorption for multiple myeloma patients enrolled in a clinical trial of anti-idiotype vaccination. British Journal of Haematology 2002; 121: 240–250
   Web of Science ®Google Scholar
• Reichardt V L, Milazzo C, Brugger W, Einsele H, Kanz L, Brossart P. Idiotype vaccination of multiple myeloma patients using monocyte-derived dendritic cells. Haematologica 2003; 88: 1139–1149
   PubMed Web of Science ®Google Scholar
• Reichardt V L, Okada C Y, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma—a feasibility study. Blood 1999; 93: 2411–2419
   PubMed Web of Science ®Google Scholar
• Maier T, Tun-Kyi A, Tassis A, et al. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 2003; 102: 2338–2344
   PubMed Web of Science ®Google Scholar
• Timmerman J M, Czerwinski D K, Davis T A, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 2002; 99: 1517–1526
   PubMed Web of Science ®Google Scholar
• Davis T A, Hsu F J, Caspar C B, et al. Idiotype vaccination following ABMT can stimulate specific anti-idiotype immune responses in patients with B cell lymphoma. Biology of Blood Marrow Transplantation 2001; 7: 517–522
   PubMed Web of Science ®Google Scholar
• Zöller M. Tumor vaccination after allogeneic bone marrow cell reconstitution of the nonmyeloablative conditioned tumor-bearing murine host. Journal of Immunology 2003; 171: 6941–6953
   PubMed Web of Science ®Google Scholar
• Zeis M, Frenzke H, Schmitz N, Uharek L, Stenmann J. Idiotype protein-pulsed dendritic cells produce a strong anti-myeloma effects after syngeneic stem cell transplantation. Bone Marrow Transplantation 2002; 29: 213–221
   PubMed Web of Science ®Google Scholar